Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

BACKGROUND: Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid hormone h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichii, Mitsuru, Mori, Katsuhito, Miyaoka, Daichi, Sonoda, Mika, Tsujimoto, Yoshihiro, Nakatani, Shinya, Shoji, Tetsuo, Emoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981856/
https://www.ncbi.nlm.nih.gov/pubmed/33743638
http://dx.doi.org/10.1186/s12882-021-02304-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981856/
https://www.ncbi.nlm.nih.gov/pubmed/33743638
http://dx.doi.org/10.1186/s12882-021-02304-2

Ejemplares similares